WILMINGTON, Mass., June 27, 2011 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc.® (Nasdaq:DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that it has been added to the U.S. broad-market Russell 3000® Index. Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on June 24, 2011. The updated list can be found at www.russell.com/indexes.
"2010 was a great year for DUSA, followed by strong first quarter 2011 results," stated Robert Doman, President and CEO. "Our financial performance is driving interest in the company and with mid single-digit market penetration in the actinic keratoses market which is served by our approved product, Levulan PDT, we believe we have significant opportunities for future growth. Being added to the Russell 3000 index is the latest in a series of positive developments for the company."
Annual reconstitution of Russell's U.S. indexes captures and ranks the 4,000 largest U.S. stocks as of the end of May by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies.
More information about Russell Indexes is available at http://www.russell.com/Indexes/data/default.asp.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform and other dermatology products. Levulan® Kerastick® (aminolevulinic acid HCl) for Topical Solution, 20%, plus DUSA's BLU-U® Blue Light Photodynamic Therapy Illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. DUSA also sells other dermatology products, including ClindaReach® (Clindamycin Phosphate Topical Solution USP, 1%) Pledgets. DUSA is based in Wilmington, Mass. Please visit our website at www.dusapharma.com.
About Russell:
Russell Investments provides strategic advice, implementation, performance benchmarks and a range of institutional-quality investment products. Russell serves individual, institutional and advisor clients in more than 35 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company.
Forward Looking Statements
Except for historical information, this news release contains certain forward-looking statements that represent our current expectations and beliefs concerning future events, and involve certain known and unknown risk and uncertainties. These forward-looking statements relate to beliefs concerning the Company's opportunities for growth. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from future results, performance or achievements expressed or implied by those in the forward-looking statements made in this release. These factors include, without limitation, actions by regulatory authorities, the status of our patent portfolio, action of third parties, and other risks and uncertainties identified in DUSA's Form 10-K for the year ended December 31, 2010.